498580-78-2

Usage

Heterocyclic compound

The structure of the compound contains both pyrazole and pyridine rings, which consist of a mix of carbon and nitrogen atoms.

Pyrazolo-pyridine structure

The compound has a unique structure that fuses a pyrazole ring with a pyridine ring.

Pyrazole derivative

The compound is classified as a derivative of pyrazole, which is a five-membered heterocyclic ring with three carbon and two nitrogen atoms.

Potential pharmaceutical applications

Due to its interesting structural features, the compound may have potential uses in the pharmaceutical industry and drug discovery.

Scientific and industrial applications

The chemical properties and potential uses of 1H-Pyrazolo[3,4-b]pyridin-3-amine,4-methyl-(9CI) may warrant further study and exploration in various scientific and industrial fields.

Upstream product

• 498580-77-1 4-methyl-2-methylthiopyridine-3-carbonitrile 
• 169141-80-4 4-methyl-2-sulfanylpyridine-3-carbonitrile 
• 65169-38-2 2-chloro-4-methyl-3-pyridinecarbonitrile 
• 498580-71-5 4-methyl-2-thioxo-1,2,3,4-tetrahydro-pyridine-3-carbonitrile 

Relevant academic research and scientific papers

(AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Synthesis of 2-thioxohydropyridine-3-carbonitrile, 2-alkylthiopyridine, thienopyridine, pyrazolopyridine derivatives and their theoretical calculations

Cyanothioacetamide (1) reacted with but-2-enal (2) to give the corresponding 4-methyl-2-sulfanyl-pyridine-3-carbonitrile (7) which was used as a good starting material for the synthesis of 1-(3-amino-4-methylthieno[2,3-b] pyridin-2-yl)ethan-1-one (10), 3-amino-4-methylthieno[2,3-b]pyridine-2- carboxamide (15), 3-amino-4-methylthieno[2,3-b]pyridine-2-carboxylate (18) and 3-amino-4-methylthieno[2,3-b]pyridin-2-ylarylketone 25a-c through its reactions with each of (1-chloroacetone (8), 3-chloropentane-2,4-dione (11) or ethyl 2-chloro-3-oxo-butanoate (19)), 2-chloroacetamide (13), ethyl 2-chloroacetate (16) and 2-bromo-1-arylethan-1-one 23a-c, respectively. Considering the data of elemental analyses, IR, 1H NMR, mass spectra and theoretical calculations, structures of the newly synthesized heterocyclic compounds were elucidated.